checkmate 817: first-line nivolumab ipilimumab in ecog ps 2 & other special advanced nsclc
Published 4 years ago • 268 plays • Length 7:59Download video MP4
Download video MP3
Similar videos
-
7:08
checkmate 817 dual immune-checkpoint inhibition in ecog ps 2
-
3:32
researcher comment: checkmate 817 trial of nivolumab–ipilimumab | fabrice barlesi
-
6:13
checkmate-227: testing ipilimumab/nivolumab in nsclc
-
6:03
checkmate 9la: nivolumab, ipilimumab and chemotherapy for stage iv nsclc
-
0:39
dr. lopes on the fda approval of nivolumab/ipilimumab in nsclc
-
4:05
checkmate 9la: first-line nivolumab ipilimumab 2 cycles chemotherapy vs 4 cycles chemo in an...
-
4:50
ipilimumab/nivolumab in first-line mrcc
-
3:14
comment: nivolumab plus ipilimumab combination for advanced nsclc
-
5:22
checkmate 743: first-line nivolumab plus ipilimumab vs chemotherapy in patients with unresectabl...
-
1:52
hcrn gu16-260: nivolumab and salvage nivolumab ipilimumab in treatment-naïve patients with adv...
-
1:34
fda approves frontline nivolumab for advanced melanoma
-
1:11
checkmate-8hw: nivolumab and ipilimumab in msi-h/dmmr mcrc
-
2:00
checkmate 8hw: first-line nivolumab plus ipilimumab in msi-h/dmmr mcrc
-
5:43
checkmate 9la trial on nivolumab plus ipilimumab for nsclc
-
0:49
scandium 2: ihp with ipilimumab and nivolumab in uveal melanoma metastases
-
5:10
checkmate 214: patterns of progression with nivolumab plus ipilimumab versus sunitinib for rcc
-
1:02
dr. hellmann on nivolumab in combination with ipilimumab for small cell lung cancer
-
3:59
checkmate 067 - combined nivolumab and ipilimumab
-
2:06
checkmate-743 study in mesothelioma